ReviewJournal of gastrointestinal cancer2025
Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Review in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Case 25: A 37-Year-Old Woman With Fanconi Anemia and a Hepatic Mass.Journal of Korean medical science · 2026Article
- AI-Driven Radiomics Assisted Prognostic Modeling for Hepatocellular Carcinoma with Portal Vein Invasion: A Retrospective Study.Biomedicines · 2026Article
- Review
- Pathological Complete Response in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Following Conversion Therapy With TACE, HAIC, Lenvatinib, and Sintilimab: A Case Report.Clinical case reports · 2026Article
- Survival Benefit of Combined Systemic and Locoregional Therapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score-Matched Analysis.Liver cancer · 2026Article
- Transarterial infusion chemotherapy combined with lenvatinib and tislelizumab versus intravenous chemotherapy for unresectable pancreatic ductal adenocarcinoma: a retrospective propensity score matching analysis.Frontiers in oncology · 2026Article
- Imaging Features of Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis Surviving Beyond 1 Year After Combined Therapy.Diagnostics (Basel, Switzerland) · 2025Article
- Histotripsy for portal vein tumor thrombus in a patient with hepatocellular carcinoma: a case report.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Portal vein tumor thrombus (PVTT) develops in up to half of patients with hepatocellular carcinoma (HCC) and historically signifies advanced-stage disease with limited treatment options and poor prognosis. Systemic therapy has been the standard treatment for HCC with PVTT, but this review highlights the potential of image-guided locoregional therapies including transarterial chemoembolization (TACE), transarterial embolization (TAE) radioembolization (TARE), hepatic arterial infusion chemotherapy (HAIC), and ablative or radiotherapeutic approaches to improve outcomes in this challenging context. We will summarize current evidence and clinical experience demonstrating that these modalities can achieve meaningful tumor control and extend survival, especially when tailored to tumor burden and PVTT extent or combined with systemic treatments. These findings underscore that aggressive locoregional treatment can be a valuable component of multidisciplinary management for advanced HCC, offering select patients an improved prognosis despite PVTT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.